Advertisement
Screener

AbbVie Inc. (ABBV) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax

AbbVie Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax

AbbVie Inc. (ABBV) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax of -$2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax · last filed 2026-08-03

  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for the quarter ending 2026-06-30 was -$2.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for the quarter ending 2026-03-31 was $0.00.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for the quarter ending 2025-12-31 was -$97.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for the quarter ending 2025-09-30 was -$1.00M, a 200.00% decline year-over-year.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2025 was -$98.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2024 was -$206.00M, a 3533.33% decline from fiscal 2023.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2023 was $6.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2022 was -$272.00M.
Period endOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 3 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 6 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 9 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 12 month
2026-06-30-$2.00M
10-Q · filed 2026-08-03
-$2.00M
10-Q · filed 2026-08-03
-$99.00M
derived: sum of 3 quarters · filed 2026-08-03
-$100.00M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31$0.00
10-Q · filed 2026-05-08
-$97.00M
derived: sum of 2 quarters · filed 2026-05-08
-$98.00M
derived: sum of 3 quarters · filed 2026-05-08
-$98.00M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31-$97.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20
-$98.00M
derived: sum of 2 quarters · filed 2026-02-20
-$98.00M
derived: sum of 3 quarters · filed 2026-08-03
-$98.00M
10-K · filed 2026-02-20
2025-09-30-$1.00M
10-Q · filed 2025-11-04
-$1.00M
derived: sum of 2 quarters · filed 2026-08-03
-$1.00M
10-Q · filed 2025-11-04
-$204.00M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30$0.00
10-Q · filed 2026-08-03
$0.00
10-Q · filed 2026-08-03
-$203.00M
derived: sum of 3 quarters · filed 2026-08-03
-$202.00M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31$0.00
10-Q · filed 2026-05-08
-$203.00M
derived: sum of 2 quarters · filed 2026-05-08
-$202.00M
derived: sum of 3 quarters · filed 2026-05-08
-$205.00M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31-$203.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20
-$202.00M
derived: sum of 2 quarters · filed 2026-02-20
-$205.00M
derived: sum of 3 quarters · filed 2026-02-20
-$206.00M
10-K · filed 2026-02-20
2024-09-30$1.00M
10-Q · filed 2025-11-04
-$2.00M
derived: sum of 2 quarters · filed 2025-11-04
-$3.00M
10-Q · filed 2025-11-04
$14.00M
derived: sum of 4 quarters · filed 2026-02-20
2024-06-30-$3.00M
10-Q · filed 2025-08-04
-$4.00M
10-Q · filed 2025-08-04
$13.00M
derived: sum of 3 quarters · filed 2026-02-20
$12.00M
derived: sum of 4 quarters · filed 2026-02-20
2024-03-31-$1.00M
10-Q · filed 2025-05-09
$16.00M
derived: sum of 2 quarters · filed 2026-02-20
$15.00M
derived: sum of 3 quarters · filed 2026-02-20
$19.00M
derived: sum of 4 quarters · filed 2026-02-20
2023-12-31$17.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20
$16.00M
derived: sum of 2 quarters · filed 2026-02-20
$20.00M
derived: sum of 3 quarters · filed 2026-02-20
$6.00M
10-K · filed 2026-02-20
2023-09-30-$1.00M
10-Q · filed 2024-11-04
$3.00M
derived: sum of 2 quarters · filed 2024-11-04
-$11.00M
10-Q · filed 2024-11-04
-$248.00M
derived: sum of 4 quarters · filed 2025-02-14
2023-06-30$4.00M
10-Q · filed 2024-08-07
-$10.00M
10-Q · filed 2024-08-07
-$247.00M
derived: sum of 3 quarters · filed 2025-02-14
-$261.00M
derived: sum of 4 quarters · filed 2025-02-14
2023-03-31-$14.00M
10-Q · filed 2024-05-03
-$251.00M
derived: sum of 2 quarters · filed 2025-02-14
-$265.00M
derived: sum of 3 quarters · filed 2025-02-14
-$276.00M
derived: sum of 4 quarters · filed 2025-02-14
2022-12-31-$237.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14
-$251.00M
derived: sum of 2 quarters · filed 2025-02-14
-$262.00M
derived: sum of 3 quarters · filed 2025-02-14
-$272.00M
10-K · filed 2025-02-14
2022-09-30-$14.00M
10-Q · filed 2023-11-06
-$25.00M
derived: sum of 2 quarters · filed 2023-11-06
-$35.00M
10-Q · filed 2023-11-06
-$109.00M
derived: sum of 4 quarters · filed 2024-02-20
2022-06-30-$11.00M
10-Q · filed 2023-08-07
-$21.00M
10-Q · filed 2023-08-07
-$95.00M
derived: sum of 3 quarters · filed 2024-02-20
-$112.00M
derived: sum of 4 quarters · filed 2024-02-20
2022-03-31-$10.00M
10-Q · filed 2023-05-05
-$84.00M
derived: sum of 2 quarters · filed 2024-02-20
-$101.00M
derived: sum of 3 quarters · filed 2024-02-20
-$115.00M
derived: sum of 4 quarters · filed 2024-02-20
2021-12-31-$74.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20
-$91.00M
derived: sum of 2 quarters · filed 2024-02-20
-$105.00M
derived: sum of 3 quarters · filed 2024-02-20
-$124.00M
10-K · filed 2024-02-20
2021-09-30-$17.00M
10-Q · filed 2022-11-04
-$31.00M
derived: sum of 2 quarters · filed 2022-11-04
-$50.00M
10-Q · filed 2022-11-04
$34.00M
derived: sum of 4 quarters · filed 2023-02-17
2021-06-30-$14.00M
10-Q · filed 2022-08-04
-$33.00M
10-Q · filed 2022-08-04
$51.00M
derived: sum of 3 quarters · filed 2023-02-17
$41.00M
derived: sum of 4 quarters · filed 2023-02-17
2021-03-31-$19.00M
10-Q · filed 2022-05-06
$65.00M
derived: sum of 2 quarters · filed 2023-02-17
$55.00M
derived: sum of 3 quarters · filed 2023-02-17
$43.00M
derived: sum of 4 quarters · filed 2023-02-17
2020-12-31$84.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17
$74.00M
derived: sum of 2 quarters · filed 2023-02-17
$62.00M
derived: sum of 3 quarters · filed 2023-02-17
$47.00M
10-K · filed 2023-02-17
2020-09-30-$10.00M
10-Q · filed 2021-11-02
-$22.00M
derived: sum of 2 quarters · filed 2021-11-02
-$37.00M
10-Q · filed 2021-11-02
$305.00M
derived: sum of 4 quarters · filed 2022-02-18
2020-06-30-$12.00M
10-Q · filed 2021-08-02
-$27.00M
10-Q · filed 2021-08-02
$315.00M
derived: sum of 3 quarters · filed 2022-02-18
$308.00M
derived: sum of 4 quarters · filed 2022-02-18
2020-03-31-$15.00M
10-Q · filed 2021-05-07
$327.00M
derived: sum of 2 quarters · filed 2022-02-18
$320.00M
derived: sum of 3 quarters · filed 2022-02-18
$314.00M
derived: sum of 4 quarters · filed 2022-02-18
2019-12-31$342.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18
$335.00M
derived: sum of 2 quarters · filed 2022-02-18
$329.00M
derived: sum of 3 quarters · filed 2022-02-18
$323.00M
10-K · filed 2022-02-18
2019-09-30-$7.00M
10-Q · filed 2020-11-04
-$13.00M
derived: sum of 2 quarters · filed 2020-11-04
-$19.00M
10-Q · filed 2020-11-04
2019-06-30-$6.00M
10-Q · filed 2020-08-04
-$12.00M
10-Q · filed 2020-08-04
2018-12-31-$35.00M
10-K · filed 2021-02-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Merck & Co., Inc. (MRK)United States$365.215B99.96
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60